Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry

NCT04688190 · View on ClinicalTrials.gov ↗

Study Summary

This multinational, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent transcatheter mitral valve implantation (TMVI), in comparison to those screened for TMVI but deemed ineligible, who subsequently underwent interventional mitral valve edge-to-edge repair, mitral valve surgery or medical/conservative therapy.

Conditions Studied

Study Locations (20)

Other

  • St Vincent's Hospital — Sydney
  • Toronto Heart Center — Toronto
  • St. Paul's Hospital — Vancouver
  • Rigshospitalet — Copenhagen
  • CHU Bordeaux — Bourdeaux
  • Lille University Hospital — Lille
  • Civils Hospices of Lyon — Lyon
  • Clinique Pasteur — Toulouse
  • HDZ Bad Oeynhausen — Bad Oeynhausen
  • German Heart Center Berlin — Berlin
  • Heart Center Bonn — Bonn
  • University Hospital of Cologne — Cologne
  • Goethe-Universität - University Hospital Frankfurt — Frankfurt
  • University Heart and Vascular Center Hamburg — Hamburg
  • Heart Center of the University Medical Center Mainz — Mainz
  • German Heart Centre Munich — Munich
  • LMU Munich — Munich

California

  • Cedars-Sinai Medical Center, Los Angeles — Los Angeles

Massachusetts

  • Brigham and Women's Hospital — Boston

Texas

  • Houston Methodist Hospital — Houston

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2020-11-01
Est. Completion 2030-12-31

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04688190

The ClinicalTrials.gov registry entry for NCT04688190 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Universitätsklinikum Hamburg-Eppendorf, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Mitral Regurgitation appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04688190 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Other, California, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04688190 about?

NCT04688190 is a clinical study titled "CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry". This multinational, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent transcatheter mitral valve implantation (TMVI), in comparison to those screened for TMVI but deemed ineligible, who subsequently underwent interventional mitral valve edge-to-edge ...

What is the current status of trial NCT04688190?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2020-11-01. Estimated completion is 2030-12-31.

What conditions does trial NCT04688190 study?

This clinical trial studies the following conditions: Mitral Regurgitation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT04688190?

This trial is sponsored by Universitätsklinikum Hamburg-Eppendorf, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04688190 being conducted?

This trial has 20 study locations across California, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial